Photo courtesy of Janssen Pharmaceutical Companies. From left to right: panel moderator Patrick Wayte, Dr. C. Michael Gibson and Dr. Paul Stoffels.
Due to the promises of lower costs, simple scaling and greater patient engagement, digital technologies are all but an inevitability for the drug trials of tomorrow, according to experts from pharma and the clinical research community speaking this weekend at the American Heart Association Scientific Sessions in Philadelphia.
These comments were accompanied by the official kickoff of CHIEF-HF,...
This morning Biofourmis, maker of an artificial intelligence-enabled monitoring and decision support platform, announced its plans to acquire Zürich, Switzerland-based wearable biosensor company Biovotion. The terms of the deal are not disclosed; however, we do know the deal is made up of a combination of cash and equity.
The acquisition will include Biovotion’s clinical grade-wearable...
Health tech manufacturer Phillips-Medisize has announced the opening of a global innovation and development centre in Copenhagen, Denmark to support its long-term growth plans for advanced injection, wearable devices and connected technologies.
The Molex company says it plans for the centre, based in the Teknikerbyen area, to help accelerate the creation of differentiated drug delivery devices...
Kyruus' new Patient Access Journey Report, which polled patients about their healthcare preferences, finds an appetite for a streamlined, digitally mature scheduling experience.
A robust web presence and offerings like online scheduling and telehealth are imperatives for health systems looking to stay relevant.
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions.
“We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...
The life science industry is making moves in the digital health space. In fact, within the last two years Sanofi, Novartis and GSK have all recently inked deals with digital health companies.
However, the relationship between pharma companies and digital health has not always been infallible. This week Novartis division Sandoz broke ties with its digital therapeutic partner Pear Therapeutics. ...
Fitbit will be working with the cardiovascular-focused Bristol-Myers Squibb-Pfizer Alliance to develop “educational content and guidance” that will help device owners recognize if they are at risk of atrial fibrillation, as well as to seek appropriate support and diagnosis of the condition.
A spokesperson for the companies noted that although the specifics of these programs are still in...
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics.
The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics.
“Pear and Sandoz previously signed...
Atlanta-based Florence Healthcare, a maker of software for clinical trials, has raised $7.1 million in a Series B funding round led by Fulcrum Equity Partners, with additional participation from Atrium Health and Bee Partners.
The round brings the company's total funding to at least $8.8 million, with a $1.7 million seed round from 2016.
WHAT THEY DO
Not to be confused with the UK social care...
